In accordance with a vision focused on the development and production of drugs for the senses, which is technologically complementary with our current leading market position in using the benefits of seawater for health purposes, a demanding, two-year investment cycle of constructing and equipping the new facility for the production of sterile solutions and the control and analysis laboratory has been recently finalized at the JGL site in Svilno.
Since our existing production capacities for manufacturing sterile solutions have been exhausted sooner than expected – the biggest challenge this year was to successfully finish the construction of the facility. The investment is worth € 6.1 million, it includes a P+3 building, with a surface area of 430 m2, with two storeys of work area and two storeys for technical purposes. The production of sterile forms is on the lower level, while a brand new, modern control and analysis laboratory is located on the upper floor.
The new production line will be dedicated exclusively to mechanical pump sprays which completely separate this production from other, existing sterile forms. The investment increased the production capacity by an additional 20 million units, which means that the total company volume was increased to 38 million units of sterile solutions in the form of sprays and drops. Also, since the basic standard for the pharmaceutical industry is the Good Manufacturing Practice (GMP), i.e. applying the principles of Good Manufacturing Practice (GMP), which ensures that products do not pose a risk due to inadequate safety, quality or effectiveness, both of these departments were constructed in accordance with high GMP standards.
The new Sterile Solution Department II is equipped with the latest equipment including clean rooms with a “cleanroom design”, with four GMP air purity classes D, C, B / A. Between each of them is an air lock. The control and analysis laboratory is equipped with state of the art analysis equipment, featuring laser machines for measuring the distribution size of dispersed particles from the mechanical pumps on spray products. This machine is the first of its kind in Croatia.
The products will be manufactured in various forms in 10-30 ml doses in the new sterile solutions department. This encompasses the most important JGL brand, Aqua Maris, with the most recent, innovative Meralys product line. We have also bought a separate line of autoclaves, dosing machines, labelling, cardboard packaging machines with a palletiser which will facilitate the work of the Sterile Solutions Department for these forms. It will also lead to an increased production of the existing and new ophthalmological and nasal preparations – primarily Latanoprost, Glaumax, Dorzol, Moxifloxacin.